Immune cell therapy targets rare inflammatory disease
Disease control
Recruiting now
This early-stage trial tests a new cell therapy called ACE1831 for people with IgG4-Related Disease, a rare condition causing inflammation in multiple organs. The therapy uses immune cells from healthy donors to potentially control the disease. About 30 adults with active flares …
Phase: PHASE1, PHASE2 • Sponsor: Acepodia Biotech, Inc. • Aim: Disease control
Last updated May 18, 2026 12:07 UTC